Overview
Legal name
RENEPHRA LIMITED
Region
Unknown
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
Renephra Limited
Renephra
Renephra Limited is a UK company with status active founded in 2009.
CRN
06815501
Founded
2009
Age
14
Corporate ownership
Updated 06 Jun 2026 16:52
1 level
1 ultimate controller
1
Company
Active
LTD
Renephra Limited
CRN 06815501
2
Direct and ultimate controller
Active
LLP
Deepbridge Capital LLP
CRN OC356449
Company events
Reference milestones and recent Companies House filing stream events.
1 event
10 Feb
2009
Incorporated
InceptionCompany registered at Companies House
Public funding
4 awards
First funded
2011
Funded years
2011, 2015, 2018, 2019, 2020
Age at first award
2 years
Projects
2020
Feasibility Studies
Lead participant
Transdermal Fluid Removal - a novel community-based and patient self-administered treatment for fluid overload in heart failure [Continuity]
1 Jun 2020 to 31 Mar 2021
Awarded
£82,336
Total cost £145,817
no public description
2019
Collaborative R&D
Lead participant
Transdermal Fluid Removal - a novel community-based and patient self-administered treatment for fluid overload in heart failure
1 Dec 2019 to 30 Apr 2021
Awarded
£59,215
Total cost £236,858
Many heart-failure patients suffer from excessive fluid accumulation, causing swelling and breathing problems. Some of these patients do not respond to treatment with water pills (diuretics). Such patients need frequent admissions to hospital for intravenous diuretics and in extreme cases, dialysis. This is inconvenient for patients, sometimes has little ...
2018
Feasibility Studies
Lead participant
Transdermal Fluid Removal - a novel community-based and patient self-administered treatment for fluid overload in heart failure
1 Mar 2018 to 30 Nov 2018
Awarded
£71,705
Total cost £102,435
"Many heart-failure patients suffer from excessive fluid accumulation, causing swelling and breathing problems. Some of these patients do not respond to treatment with water pills (diuretics). Such patients need frequent admission to hospital for intravenous diuretics and in extreme cases, dialysis. This is inconvenient for patients, sometimes has little ...
2015
GRD Proof of Market
Lead participant
Renephra Ltd. Validating commercial opportunity for a novel medical device to treat fluid overload
1 May 2015 to 31 Jan 2016
Awarded
£25,000
Total cost £75,000
The objective of the proposed study is to evaluate a commercial potential for the proposed novel minimally invasive device for fluid overload treatment and to shape a business plan for advancing commercialization of this technology. The TSB funding of this project will enable the technology to progress to the stage where private funding can be raised to d...
2011
GRD Development of Prototype
Lead participant
Renephra Ltd
1 Oct 2011 to 30 Jun 2013
Awarded
£250,001
Total cost £789,891
Dialysis is the current mainstream treatment for patients suffering kidney failure. During treatment the quality of life for patients is very poor, treatment in hospital three times a week prevents many patients from working, survival rates are less than 50% at 5 years, and the cost to the state approximates £30k per annum per patient. We have a technolog...
Product types
Collaborative R&D
Feasibility Studies
GRD Development of Prototype
GRD Proof of Market